Suven Life Sciences updates on Phase-2b clinical trial of Ropanicant
Suven Life Sciences announced that the first patient has been randomized in its Phase-2b clinical trial evaluating Ropanicant, a novel oral α4β2 nicotinic acetylcholine receptor (nAChR) antagonist, for the treatment of Major Depressive Disorder (MDD).
The Phase-2b double blinded, placebo controlled study builds on the positive results of the completed Phase-2a trial, which demonstrated favorable safety, clinically meaningful and significant improvement in depressive symptoms from baseline based on the Montgomery berg Depression Rating Scale (MADRS) score, with indication of rapid onset of action in MDD patients distinguishing Ropanicant from existing standard therapies. Insights from Phase-2a evolved the study design, dose selection, and dosing regimen for the current Phase 2b trial being conducted in exclusively in USA under FDA IND.
"Randomizing the first patient in our Phase-2b study of Ropanicant is an important milestone for Suven Life Sciences. It reflects our continued commitment to developing innovative treatments for patients suffering from MDD. said Venkat Jasti, Chairman and MD of Suven Life Sciences.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
16-07-2025
- Business Standard
Suven Life Sciences updates on Phase-2b clinical trial of Ropanicant
For treatment of Major Depressive Disorder Suven Life Sciences announced that the first patient has been randomized in its Phase-2b clinical trial evaluating Ropanicant, a novel oral α4β2 nicotinic acetylcholine receptor (nAChR) antagonist, for the treatment of Major Depressive Disorder (MDD). The Phase-2b double blinded, placebo controlled study builds on the positive results of the completed Phase-2a trial, which demonstrated favorable safety, clinically meaningful and significant improvement in depressive symptoms from baseline based on the Montgomery berg Depression Rating Scale (MADRS) score, with indication of rapid onset of action in MDD patients distinguishing Ropanicant from existing standard therapies. Insights from Phase-2a evolved the study design, dose selection, and dosing regimen for the current Phase 2b trial being conducted in exclusively in USA under FDA IND. "Randomizing the first patient in our Phase-2b study of Ropanicant is an important milestone for Suven Life Sciences. It reflects our continued commitment to developing innovative treatments for patients suffering from MDD. said Venkat Jasti, Chairman and MD of Suven Life Sciences.
Time of India
18-06-2025
- Time of India
Not everyone needs magnesium supplements: Here's who should skip it
Magnesium supplements are very much praised as cure-alls; better sleep, reduced muscle cramps, improved heart health, and even lower stress levels. After all, who wouldn't want a calm mind and smooth digestion? But did you know that magnesium is not always the hero? In certain health conditions or situations, magnesium can do more harm than good. While the general belief is that it's safe because it's 'just a mineral,' the truth lies in the details. A recent trial studied 60 patients diagnosed with Major Depressive Disorder (MDD) under standard SSRI (Selective Serotonin Reuptake Inhibitor) treatment. Half of the group received magnesium supplements for six weeks, while the other half took a placebo. The results? By the fourth and sixth weeks, those who took magnesium showed significantly lower depression scores, as measured by the Beck II test. While the improvement wasn't noticeable in the initial weeks, sustained intake seemed to make a difference. The study concluded that magnesium could be a promising add-on to SSRIs in managing MDD symptoms — especially in patients who don't respond fully to antidepressants alone. However, experts caution that more extensive studies are needed before magnesium can be recommended as a standard part of depression treatment Here's all we need to know about the groups that should think twice before reaching for that magnesium bottle; not out of fear, but out of knowledge. Our kidneys perform one of the most important functions of the body, that is filtering waste and toxins from the blood, balancing fluids, and maintaining overall health. It is extremely important to keep your kidneys healthy, as long term kidney abuse can even lead to a complete and irreversible kidney failure. People with kidney troubles The kidneys are the main filter for excess magnesium in the body. When the kidneys aren't functioning properly, as in chronic kidney disease, magnesium doesn't get excreted as efficiently. This can lead to a dangerous condition called hypermagnesemia (excess magnesium in the blood). Symptoms may start mild, nausea, weakness, but can progress to slow heartbeat, confusion, or even cardiac arrest in severe cases. It's not about the magnesium being 'bad'; it's about the body being unable to handle even the good stuff when it's already struggling. Those on certain medications Magnesium supplements can mess with how certain drugs work in the body. A few examples: Antibiotics (like tetracyclines and quinolones): Magnesium can bind to them in the gut and make them less effective. Diuretics (water pills): Some can lead to magnesium loss, while others can cause magnesium levels to rise dangerously. Heart medications (like digoxin): Magnesium affects heart rhythm, which can be risky when mixed with heart drugs. Mostly, these interactions happen silently, and symptoms only show up once the balance is off. According to experts, magnesium is needed for mitochondrial energy production in liver cells, turning on enzymes that help with protein making, glucose use, fat metabolism, and building genetic material. All this is important for the liver to work properly. People with slow heart rhythms While magnesium does support heart rhythm, it can worsen bradycardia (an already slow heartbeat). For someone who has naturally slow pulses or underlying conduction issues, extra magnesium may slow things down too much, leading to dizziness, fainting, or fatigue. It's not about magnesium being harmful universally, but about how it behaves in a body that already runs a little too slow. Those with frequent loose stools or gut sensitivities Certain forms of magnesium, especially magnesium citrate and magnesium oxide, are known to have a laxative effect. For someone already dealing with IBS, sensitive digestion, or frequent diarrhoea, this can make things worse. Instead of calming the gut, it could irritate it further, leading to dehydration, electrolyte imbalances, and stomach cramping. This often goes unnoticed because people assume any discomfort is just 'cleansing.' But if the body is already trying to calm itself, magnesium may be an unwanted nudge. Habits to Boost Longevity and Health People with a history of very low blood pressure Magnesium lowers blood pressure, great news, right? Yes, magnesium can help manage high blood pressure . But in people with naturally low blood pressure, it might bring the numbers too far down. Symptoms like lightheadedness, blurred vision, or fatigue might seem vague, but they often point to an over-relaxed circulatory system. When magnesium enters the mix, it can amplify the dip, especially in combination with blood pressure medications or hot weather. One step to a healthier you—join Times Health+ Yoga and feel the change
Hans India
10-06-2025
- Hans India
Childhood trauma can have lasting brain consequences, cause psychiatric disorders
Childhood adversity may have a profound connection with lifelong vulnerability causing psychiatric disorders and other brain consequences, according to a study. The study showed that early life experiences become biologically embedded and create lasting changes in brain structure and immune function. "The immune system doesn't just fight infections -- it plays a crucial role in shaping our mental health throughout life," said Sara Poletti, senior researcher at IRCCS Ospedale San Raffaele Milan, Italy. "Childhood trauma can fundamentally reprogramme these immune responses, creating vulnerability to depression, bipolar disorder, and other psychiatric conditions decades later," she added. By identifying specific inflammatory markers associated with childhood trauma, the study provides potential targets for novel interventions. The research calls for precision medicine approach to transform psychiatric treatment from symptom management to addressing underlying biological mechanisms. The paper, published in the journal Brain Medicine focussed on the use of an immunomodulatory agent (interleukin 2) to treat mood disorders. Mood disorders have been recognised by the World Health Organization (WHO) as a major source of disability, morbidity, and mortality worldwide. Among mood disorders, major depressive disorder (MDD) and bipolar disorders (BD) are the most frequent and disabling ones. The lifetime prevalence is about 12 per cent for MDD and 2 per cent for BD. Recent years have seen evidence increasing for the role of immune dysregulations in mood disorders with a focus on the inflammatory response system (IRS). It suggests that an activation of the IRS should be considered as one of the main pathological underpinnings of mood disorders. "I aim to further elucidate the role of the immune system and its interaction with the environment in psychiatric disorders," Poletti said. Her vision includes developing prevention strategies to reduce mental illness odds, particularly for individuals with trauma histories. This preventive focus represents a paradigm shift from reactive to proactive psychiatric care.
